Conmed (CNMD) EPS (Weighted Average and Diluted) (2010 - 2026)

Conmed has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at $0.45 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 136.84% year-over-year to $0.45; the trailing twelve-month figure through Mar 2026 stood at $1.77 (down 53.42% YoY), and the FY2025 full-year result was $1.51, down 64.47% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.45, down from $0.54 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $1.57 in Q3 2024, with the low at -$5.65 in Q2 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.32 across 5 years, with a median of $0.54 in 2025.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) slumped 1478.05% — and 2024, when it jumped 950.0%.
• Conmed's EPS (Weighted Average and Diluted) stood at $0.91 in 2022, then advanced by 15.38% to $1.05 in 2023, then increased by 2.86% to $1.08 in 2024, then slumped by 50.0% to $0.54 in 2025, then declined by 16.67% to $0.45 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.45 (Q1 2026), $0.54 (Q4 2025), and $0.09 (Q3 2025), per Business Quant data.